Searching for ideal dendritic cell for cancer vaccines
| Authors | |
|---|---|
| Year of publication | 2008 |
| Type | Conference abstract |
| MU Faculty or unit | |
| Citation | |
| Description | Dendritic cells (DC) are antigen-presenting cells that are able to activate both helper and cytotoxic T-lymphocytes and induce antitumour immunity. That makes them a suitable source for in vitro cancer vaccines production. Dendritic cells for clinical application should produce high levels of interleukin-12 (IL-12), which supports antitumour response of the immune system. In this study different conditions of the DC maturation and their effect on the DC immunophenotype and IL-12 production were compared. For clinical grade DC preparations maturation with bacterial lipopolysaccharide (LPS) and interferon-gamma seems to be the most suitable combination. |
| Related projects: |